882 related articles for article (PubMed ID: 23927379)
1. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
2. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
[TBL] [Abstract][Full Text] [Related]
4. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous manifestations in inflammatory bowel disease.
Tromm A; May D; Almus E; Voigt E; Greving I; Schwegler U; Griga T
Z Gastroenterol; 2001 Feb; 39(2):137-44. PubMed ID: 11253504
[TBL] [Abstract][Full Text] [Related]
6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
7. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
8. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
10. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
11. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.
Ciccacci C; Biancone L; Di Fusco D; Ranieri M; Condino G; Giardina E; Onali S; Lepre T; Pallone F; Novelli G; Borgiani P
J Crohns Colitis; 2013 Feb; 7(1):44-52. PubMed ID: 22445837
[TBL] [Abstract][Full Text] [Related]
12. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services' Adult Hospital 1998-2009.
Polcz M; Gu J; Florin T
J Crohns Colitis; 2011 Apr; 5(2):148-51. PubMed ID: 21453884
[TBL] [Abstract][Full Text] [Related]
13. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
Károlyi Z; Erós N; Ujszászy L; Nagy G
Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
[TBL] [Abstract][Full Text] [Related]
14. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease.
Menachem Y; Gotsman I
Isr Med Assoc J; 2004 Feb; 6(2):88-90. PubMed ID: 14986464
[TBL] [Abstract][Full Text] [Related]
15. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
[TBL] [Abstract][Full Text] [Related]
17. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease.
Freeman HJ
Can J Gastroenterol; 2005 Oct; 19(10):603-6. PubMed ID: 16247522
[TBL] [Abstract][Full Text] [Related]
18. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
